Figure 5.

ETV1 p.E462Q and p.P159S mutations induced gefitinib and osimertinib resistance in vitro. H358 cells harboring EGFR L858R and T790M plus indicated mutations were treated with osimertinib (A) or gefitinib (B) at the indicated concentrations. Cell viability was detected after 24 hours of treatment and plotted for comparison with untreated control cells. (C) IC50 values of different EGFR mutant cell lines to osimertinib and gefitinib treatment were plotted in bar graphs for comparison. Experiments were repeated twice in triplicate each time and the mean ± standard deviation value was plotted at each concentration. ***, P<0.001. EGFR, epidermal growth factor receptor; ETV1, ETS variant transcription factor 1.